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Abstract
We investigated whether a history of endoscopic tumor ablation impacts oncologic outcomes after radical ne-
phroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Using a multi-institutional da-
tabase that contained patients who were treated with RNU, oncologic outcomes were assessed according to
history of ureteroscopic tumor ablation. Disease-free survival (DFS) and cancer-specific survival (CSS) were
estimated using the Kaplan-Meier survival analysis. Multivariate Cox regression analyses were performed to
determine independent predictors of disease recurrence and cancer-specific mortality after RNU. The study
included 1268 patients, 853 men and 415 women, with a mean age of 67.5 years (range 32–94 y) and 52.8 months
median follow-up after RNU. A total of 175 (13%) patients underwent RNU after endoscopic tumor ablation and
1093 (87%) patients underwent RNUwithout a history of endoscopic ablation. The 5-year DFS and CSS rates were
72% and 77% in those with a history of tumor ablation vs 69% and 73% in those without a history of ablation
(P¼ 0.171 and P¼ 0.365, respectively). In multivariate Cox regression analysis, history of ablation therapy was
not associated with disease recurrence or cancer-specific mortality (hazard ratio [HR]: 0.79, P¼ 0.185 and HR: 0.7,
P¼ 0.078, respectively). Our collaborative international efforts suggest that in selected patients, endoscopic tumor
ablation does not adversely affect the recurrence and survival after subsequent RNU for UTUC. Our data support
the continued role of ureteroscopic ablation of UTUC in appropriately selected patients.
Introduction
Upper urinary tract urothelial carcinoma (UTUC)is relatively rare, accounting for approximately 5% of
genitourinary malignancies, although recent data suggest
that the incidence is increasing.1,2 The standard treatment for
most patients with localized UTUC has been radical ne-
phroureterectomy (RNU).2
Advances in flexible fiberoptic instruments and improve-
ments in laser technology have allowed for organ-sparing
endoscopic management of low-grade, low-stage UTUC.
Conflicting data exist, however, regarding the oncologic
safety of endoscopic interventions for UTUC, with theoretical
concerns centering on inadequate clinical tumor staging,
incomplete ablation, and increased risk of tumor dissemina-
tion.3,4 In addition, the impact of delay to RNU in patients
with UTUC because of an attempt at ablative therapy is not
well characterized.5 Similar to the reported experience in
bladder cancer, attempts at an endoscopic intervention before
RNUmay result in a delay to definitive surgical therapy with
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increased risks of disease progression and adverse impact on
oncologic outcome.6,7 Addressing these concerns, we sought
to retrospectively review outcomes of patients with UTUC
who were treated with endoscopic ablation before RNU
compared with those solely treated by RNU.
Patients and Methods
Patient selection
We used a database that comprised patients from the
UTUC Collaboration; this patient cohort has previously been
described in the literature.8 This was a study approved by an
Institutional Review Board, with all participating sites pro-
viding the necessary institutional data use agreements before
initiation of the study. After combining the data sets from the
enrolled centers, a database containing 1363 patients who
underwent RNU between 1987 and 2007 was generated. Ex-
cluding patients with a history of radical cystectomy and
patients who were treated with neoadjuvant chemotherapy
before RNU, the final dataset comprised 1268 patients who
were treated with RNU for UTUC. Patients were evaluated
before ureteroscopic ablation and/or RNU by cystoscopy,
retrograde ureteropyelography, ureteroscopy, and cytology/
biopsy. Staging radiologic imaging included intravenous ur-
ography (IVU), ultrasonography, and CT of the abdomen and
pelvis. Diagnostic and staging criteria varied significantly
during the time of the study and among participating centers.
Although selection criteria for ureteroscopic ablation var-
ied among participating institutions, generally endoscopic
tumor ablation was offered electively to patients with com-
pletely resected, low-grade, unifocal, noninvasive tumors.
Ureteroscopic ablation was also offered to selected patients
with high-grade bilateral tumors, renal insufficiency, tumors
in a solitary renal unit, and to persons not medically fit for
RNU. Endoscopic tumor ablation was defined as electro-
cautery or laser-based destruction of all grossly visible disease
within the upper urinary tract.9,10 RNU was performed be-
cause of tumor recurrence/persistence, not amenable to re-
peated ablation, evidence of stage or grade progression, and
patient or clinician preference.
Pathologic evaluation
All surgical specimens were processed according to stan-
dard pathologic procedures, and all slides were rereviewed
by genitourinary pathologists at participating centers ac-
cording to prospectively defined uniform criteria. All pa-
thologists were blinded to clinical outcomes. Tumors were
staged according to the sixth edition of the American Joint
Committee on Cancer-Union International Contre le Cancer
Tumor-Node-Metastasis classification.11 Tumor grades were
assessed according to the 1998 World Health Organization/
International Society of Urologic Pathology consensus classi-
fication.12
Surveillance regimen
Follow-up was performed according to institutional proto-
cols. Patients were generally followed every 3 months after
endoscopic ablation. The follow-up included cystocopy, ur-
eteroscopy, and cytology. Imaging of the upper tract by IVUor
CT was performed every 6 to 12 months. After RNU, patients
were followed every 3 months for the first year and every 6
months thereafter. Follow-up consisted of a history, physical
examination, routine blood work and serum chemistry stud-
ies, urinary cytology, chest radiography, cystoscopic evalua-
tion of the urinary bladder, and radiographic evaluation of the
contralateral upper urinary tract. Elective bone scans, chest
CT, or MRI were performed when indicated clinically.
Outcome assessment and statistical analysis
Bladder recurrences were not considered in the analysis of
disease-free survival (DFS) rate. DFS and cancer-specific
survival (CSS) were estimated using the Kaplan-Meier sur-
vival analysis. Disease recurrence was defined as local failure
in the nephroureterectomy bed, regional lymph nodes, or
distant metastasis after RNU for UTUC. The period of DFS
was defined as the time between the date of RNU and the
development of local recurrence or distant metastasis. Cen-
sored survival values represent patients who were alive
without clinical evidence of disease at the last follow-up.
Cause of death was determined by the treating physicians, by
chart review corroborated by death certificates, or by death
certificates alone. The period of CSS was defined as the time
between the date of RNU and death from cancer. Statistical
differences were determined by the log rank test. All reported
P values are two-sided, and significance was set at 0.05. Fi-
nally, multivariate Cox regression analysis was performed to
determine the independent predictors of disease recurrence
and cancer-specific mortality after RNU. All statistical tests
were performed with SPSS version 17.0.
Results
The clinical characteristics of the study population and final
pathologic findings from RNU specimens are presented in
Table 1. The cohort of 1268 patients who underwent RNU
included 853 men and 415 women with a median age of 68.5
years (range 32–94 y). Median follow-up for the whole cohort
was 52.8 months (range 3–250 mos), with a total of 175 pa-
tients undergoing RNU after endoscopic tumor ablation and
1093 patients treated with RNU without a history of tumor
ablation. Adjuvant systemic chemotherapy was administered
to 25 (14.4%) and 128 (11.7%) patients after RNU in the initial
ablation and initial RNU cohorts, respectively (P¼ 0.318).
UTUC recurred in 36 (20%) patients who were treated with
initial tumor ablation and in 303 (28%) patients who were
treated with initial RNU. Cancer-specific death was docu-
mented in 30 (17%) patients who were treated with initial
tumor ablation and in 250 (23%) patients who were treated
with initial RNU. Kaplan-Meier survival analyses demon-
strated similar recurrence and survival rates in patients after
RNU, regardless of history of endoscopic tumor ablation (Fig.
1). The 5-year DFS estimates were 72% and 69% in initial
ablation and initial RNU patients, respectively (P¼ 0.171).
The 5-year CSS estimates were 77% and 73% in initial ablation
and initial RNU patients, respectively (P¼ 0.365).
In multivariate Cox regression analyses, tumor stage,
grade, architecture, and lymph node involvement were in-
dependent predictors of DFS and CSS. History of endoscopic
tumor ablation, however, was not associated with disease
recurrence or cancer-specific mortality after RNU (hazard
ratio [HR]: 0.79, confidence interval [CI]: 0.55–1.12, P¼ 0.185
and HR: 0.70, CI: 0.48–1.04, P¼ 0.078, respectively) (Table 2).
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Discussion
It has been reported that urothelial carcinoma behaves
identically in the upper and lower urinary tracts when stage
and grade are matched.13 Because of our ability to successfully
manage appropriately selected patients with bladder cancer
cystoscopically, endoscopic management of UTUC is an at-
tractive option, potentially obviating the need for a major ex-
tirpative surgery and allowing maximal preservation of renal
function. Although advanced endourologic technologies that
are applicable to management of UTUC are currently available,
lacking appropriate clinical trials, concerns regarding oncologic
safety of their application remain. Unlike in bladder cancer,
accurate clinical staging and monitoring of UTUC is difficult,
with significant rates of upstaging and upgrading at RNU.14
Furthermore, in parallel to the bladder cancer literature, delay
to RNU attributable to understaging and inappropriate endo-
scopic management of UTUCmay negatively impact oncologic
outcomes.6,7 Finally, there are theoretical concerns about tumor
dissemination via urothelial perforation, pyelolymphatic, or
pyelovenous backflow.3,4 In addition, the effectiveness of topi-
cal immunotherapy or chemotherapy for adjuvant treatment of
upper tract urothelial tumors is unclear.
Unfortunately, there are little data that evaluate the impact
of initial endoscopic tumor ablation on survival outcomes
after RNU for UTUC. In one of the few studies that evaluate
the impact of delay to RNU in patients undergoing initial
endoscopic tumor ablation, Boorjian and collaborators5
concluded that endoscopic ablation before RNU did not ad-
versely affect the postoperative oncologic outcomes. Conclu-
sions from this study, however, may be limited by the fact that
only 12 patients in their cohort underwent RNU after ur-
eteroscopic ablation. We present one of the largest clinical
experiences in UTUC, with a significant number of patients
(175 [13%]) who were treated with initial endoscopic tumor
ablation before radical surgery. As expected, patients initially
selected for RNU were more likely to have features that
were associated with advanced UTUC, such as higher tumor
stage, presence of lymphovascular invasion, and increased
incidence of regional lymphatic metastases, compared with
patients who were initially selected for endoscopic manage-
ment. In univariate andmultivariate analysis that adjusted for
these factors, however, history of ureteroscopic ablation was
not associated with inferior DFS or CSS.
Laparoscopic RNU was performed more frequently in the
initial ablation group compared with the initial RNU group
(50% vs 20%, P¼ 0.01), suggesting the applicability of this
approach in the majority of UTUC patients in whom initial
endoscopic treatment fails. We also noted a higher probability
of ureteroscopic ablation in elderly patients. The median age
of patients who underwent initial ablation was 71 years
(range 40–94 y), and it was significantly higher than patients
Table 1. The Clinical And Pathologic Characteristics Of Patients
With Upper Urinary Tract Urothelial Carcinoma According to Initial Management Modality
Initial management
Entire cohort Ablation (175) RNU (1093) P value
Age (y) 0.011
(mean, median and range) 68.3, 69.6
(32–94)
70.3, 71.2
(40–94)
68.1, 69.2
(32–89)
Sex (%) 0.030
Female 415 (33%) 45 (25%) 370 (34%)
Male 853 (67%) 130 (75%) 723 (66%)
Tumor location (%)
Kidney 838 (66%) 105 (60%) 733 (67%) 0.067
Ureter 430 (34%) 70 (40%) 360 (33%)
RNU (%)
Open 970 (76%) 88 (50%) 882 (81%) 0.010
Laparoscopic 298 (24%) 87 (50%) 211 (19%)
Adjuvant chemotherapy (%) 153 (12%) 25 (14%) 128 (11%) 0.318
Pathologic tumor stage (%)
Ta 259 (20%) 73 (42) 186 (17%) <0.01
Tis 22 (1%) 6 (3) 16 (1%)
T1 286 (23%) 41 (23%) 245 (22%)
T2 234 (19%) 36 (21%) 216 (20%)
T3 408 (32%) 18 (10.5%) 372 (35%)
T4 59 (5%) 1 (0.5%) 58 (5%)
Pathologic grade (%)
Low 479 (38%) 69 (40%) 410 (38%) 0.627
High 789 (62%) 106 (60%) 683 (62%)
Tumor architecture (%)
Papillary 944 (74%) 133 (76%) 811 (74%) 0.612
Sesile 324 (26%) 42 (24%) 282 (26%)
Lymphovascular invasion 297 (23%) 22 (13%) 275 (25%) 0.010
Lymph node involvement 116 (9%) 6 (3%) 110 (10%) 0.050
RNU¼ radical nephroureterectomy.
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who underwent immediate RNU, whose median age was 69
years (range 32–89 y). The age-related comorbidites and the
concerns about declining global renal function may explain
why initial ablation was offered to older patients.
While endoscopic tumor ablation remains a viable option
for selected patients with UTUC, tools to improve clinical
staging and risk stratification of upper tract disease are ur-
gently needed to optimize care of these patients. Various
clinical variables, such as biopsy grade, ipsilateral hydone-
phropsis, and urine cytology have been correlated with
pathologic findings at RNU, but individual variable predic-
tive accuracy remains low.14,15 Using amultivariable outcome
model, we have recently developed a preoperative nomo-
gram, based on grade, architecture, and location of the tumor
to predict the probability of nonorgan-confined UTUC with
improved accuracy.16 Ultimately, multivariable models that
incorporate molecular tumor markers will further improve
our ability to accurately predict clinical tumor behavior.
The current study is not devoid of limitations. First, the
power of our conclusions is weakened by the retrospective
nature of the study, with inherent limitations attributable to
this study design. Furthermore, potentially important clinical
parameters, such as initial clinical tumor stage, grade, and
time from diagnosis to RNU, were not available for analysis.
Time from ureteroscopic ablation to RNU was not available
for analysis but may have had a significant impact on final
pathologic stage and oncologic outcome after RNU. Thus,
only well-designed prospective studies can confirm that delay
of RNU because of initial ureteroscopic ablation does not
compromise the oncologic outcomes of UTUC patients. With
the rarity of the disease, however, a retrospective study de-
sign, from multiple high-volume cancer centers, may provide
the best possible clinical data.
Retrospective analysis of one of the largest international
cohorts of patients who were treated with RNU for UTUC
suggests that the initial attempt at endoscopic tumor ablation
is not associated with inferior oncologic outcomes after RNU.
Our data support the continued role of ureteroscopic tumor
ablation in selected patients with UTUC. Prospective studies
are needed to confirm our findings.
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